RhIL-11治疗前后白血病患者血清血小板生成素及其受体的改变及意义

目的进一步了解血小板减少症患者血清IL-11与血小板生成素（TPO）的相互调控机制。方法应用ELISA法及实时定量PCR方法检测40例初治缓解的急性白血病患者化疗前后血清TPO及其受体c—mp1表达，其中20例应用rhIL-11为A组，20例不用rhIL-11为B组，以20例健康人为正常对照c组。结果1．血清TPO水平及其c—mpl水平：化疗前白血病A、B两组间差异无显著性（P〉0．05），白血病与正常对照间有显著性差异（P〈0．05）；化疗后血小板降低时，白血病两组间差异无显著性（P〉0．05），白血病与正常对照间有显著性差异（P〈0．05），且两组均高于化疗前；血小板恢复正常时（PLT〉100×10 9），A组明显高于B组（P〈0．05），而B组略高于c组，差异无显著性（P〉0．05）。2．相关分析：化疗前的所有样本血清TPO与血小板数呈负相关。3组的血清TPO与c—mpl水平均呈正相关关系。结论应用IL-11治疗组较未用IL—11治疗组TPO及其受体明显增高，提示IL-11与TPO有协同作用。本实验研究结果进一步探讨了血小板减少症患者IL-11的调控机制．为临床诊断、治疗血小板减少症提供新的理论依据。

Alteration and significance of serum TPO and it's receptor compared before and after treatment by RhIL-11

Objective To explore the relationship between interlukin-11 (IL-11) level and thrombopoietin (TPO) in patients with thrombocytopenia. Methods 40 acute leukemia patients diagnosed for the first time were enrolled in the study and divided into two groups at random. Group A (20cases) accepted rhIL-11 therapy after chemotherapy while groupB (20cases) didn't do as a blank control group,and group C including 20 healthy cases as a normal control one. Serum TPO levels and c-mpl levels of the three groups were deter...